BB Biotech (BION.SW) Stock Price

BB Biotech Price

SIX·CLOSED
51.50CHF+0.70 (+1.37 %)
Market closed

Revenue at BB Biotech has contracted by 7.2% per year over the past 19 years to 76.81 M CHF. Earnings per share have grown at 21.9% per year over the last 16 years. BB Biotech's net margin stands at 752.7%, up from 102.2% several years earlier. BB Biotech currently offers a dividend yield of about 7.44%. The payout ratio is around 17% of earnings. The dividend has grown at 0.2% per year over the past 15 years. Analysts set a median price target of 58.87 CHF, implying 14.3% above the current price. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 65% above its 52-week low.

BB Biotech stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of BB Biotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BB Biotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BB Biotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

BB Biotech Stock Price History
DateBB Biotech Price
8/6/202651.50 CHF
8/5/202650.80 CHF
8/4/202650.70 CHF
7/31/202651.10 CHF
7/30/202651.50 CHF
7/29/202652.40 CHF
7/28/202651.60 CHF
7/27/202652.10 CHF
7/24/202650.80 CHF
7/23/202649.65 CHF
7/22/202649.70 CHF
7/21/202650.20 CHF
7/20/202650.40 CHF
7/17/202649.55 CHF
7/16/202649.60 CHF
7/15/202649.80 CHF
7/14/202650.10 CHF
7/13/202650.50 CHF
7/10/202650.60 CHF
7/9/202651.50 CHF
7/8/202651.60 CHF
7/7/202651.90 CHF
7/6/202650.00 CHF
7/3/202650.20 CHF
7/2/202649.75 CHF
7/1/202649.10 CHF
6/30/202648.75 CHF
6/29/202647.90 CHF
6/26/202647.60 CHF
6/25/202647.80 CHF
6/24/202646.80 CHF
6/23/202646.30 CHF
6/22/202645.60 CHF
6/19/202644.65 CHF
6/18/202644.20 CHF
6/17/202642.60 CHF
6/16/202643.55 CHF
6/15/202643.95 CHF
6/12/202643.20 CHF
6/11/202642.00 CHF
6/10/202641.75 CHF
6/9/202641.40 CHF
6/8/202641.45 CHF
6/5/202642.00 CHF
6/4/202641.85 CHF
6/3/202641.55 CHF
6/2/202642.90 CHF
6/1/202644.30 CHF
5/29/202644.15 CHF
5/28/202644.25 CHF
5/27/202644.75 CHF
5/26/202644.30 CHF
5/22/202644.30 CHF
5/21/202644.20 CHF
5/20/202643.50 CHF
5/19/202643.70 CHF
5/18/202642.95 CHF
5/15/202644.70 CHF
5/13/202645.65 CHF
5/12/202645.55 CHF
5/11/202645.40 CHF
5/8/202644.75 CHF
5/7/202644.85 CHF
5/6/202645.10 CHF
5/5/202645.10 CHF
5/4/202644.30 CHF
4/30/202644.15 CHF
4/29/202644.50 CHF
4/28/202645.75 CHF
4/27/202645.40 CHF
4/24/202644.95 CHF
4/23/202646.10 CHF
4/22/202645.85 CHF
4/21/202645.75 CHF
4/20/202646.65 CHF
4/17/202646.80 CHF
4/16/202646.10 CHF
4/15/202646.25 CHF
4/14/202646.40 CHF
4/13/202646.95 CHF
4/10/202644.95 CHF
4/9/202644.95 CHF
4/8/202644.35 CHF
4/7/202643.65 CHF
4/2/202644.60 CHF
4/1/202644.40 CHF
3/31/202644.45 CHF
3/30/202643.20 CHF
3/27/202642.85 CHF
3/26/202643.30 CHF
3/25/202643.60 CHF
3/24/202642.50 CHF
3/23/202642.85 CHF
3/20/202645.40 CHF
3/19/202644.75 CHF
3/18/202645.30 CHF
3/17/202646.70 CHF
3/16/202646.10 CHF
3/13/202644.65 CHF
3/12/202645.10 CHF
3/11/202645.95 CHF
3/10/202646.45 CHF
3/9/202645.15 CHF
3/6/202645.25 CHF
3/5/202645.40 CHF
3/4/202646.15 CHF
3/3/202645.65 CHF
3/2/202647.35 CHF
2/27/202647.10 CHF
2/26/202646.35 CHF
2/25/202647.40 CHF
2/24/202647.30 CHF
2/23/202647.00 CHF
2/20/202646.45 CHF
2/19/202646.00 CHF
2/18/202646.10 CHF
2/17/202646.25 CHF
2/16/202645.05 CHF
2/13/202645.95 CHF
2/12/202645.45 CHF
2/11/202645.45 CHF
2/10/202646.15 CHF
2/9/202646.25 CHF
2/6/202646.55 CHF
2/5/202646.75 CHF
2/4/202647.20 CHF
2/3/202647.20 CHF
2/2/202647.05 CHF
1/30/202646.35 CHF
1/29/202646.70 CHF
1/28/202647.05 CHF
1/27/202648.05 CHF
1/26/202646.65 CHF
1/23/202649.50 CHF
1/22/202649.35 CHF
1/21/202648.45 CHF
1/20/202647.05 CHF
1/19/202647.85 CHF
1/16/202648.40 CHF
1/15/202648.85 CHF
1/14/202648.50 CHF
1/13/202648.10 CHF
1/12/202647.70 CHF
1/9/202647.70 CHF
1/8/202646.85 CHF
1/7/202645.70 CHF
1/6/202644.25 CHF
1/5/202643.35 CHF
12/30/202544.95 CHF
12/29/202545.15 CHF
12/23/202545.55 CHF
12/22/202546.30 CHF
12/19/202545.60 CHF
12/18/202544.85 CHF
12/17/202545.40 CHF
12/16/202545.35 CHF
12/15/202545.80 CHF
12/12/202545.40 CHF
12/11/202545.15 CHF
12/10/202545.60 CHF
12/9/202546.00 CHF
12/8/202547.10 CHF
12/5/202545.85 CHF
12/4/202545.65 CHF
12/3/202545.45 CHF
12/2/202544.50 CHF
12/1/202544.35 CHF
11/28/202545.05 CHF
11/27/202544.20 CHF
11/26/202544.55 CHF
11/25/202544.40 CHF
11/24/202543.50 CHF
11/21/202542.45 CHF
11/20/202543.20 CHF
11/19/202542.15 CHF
11/18/202542.20 CHF
11/17/202542.70 CHF
11/14/202541.65 CHF
11/13/202541.35 CHF
11/12/202541.45 CHF
11/11/202541.10 CHF
11/10/202540.75 CHF
11/7/202540.10 CHF
11/6/202540.85 CHF
11/5/202540.75 CHF
11/4/202541.05 CHF
11/3/202540.75 CHF
10/31/202541.10 CHF
10/30/202541.25 CHF
10/29/202540.90 CHF
10/28/202540.70 CHF
10/27/202541.05 CHF
10/24/202539.80 CHF
10/23/202538.25 CHF
10/22/202538.95 CHF
10/21/202539.05 CHF
10/20/202539.00 CHF
10/17/202538.45 CHF
10/16/202538.75 CHF
10/15/202538.40 CHF
10/14/202538.10 CHF
10/13/202538.15 CHF
10/10/202538.20 CHF
10/9/202539.00 CHF
10/8/202539.45 CHF
10/7/202538.95 CHF
10/6/202537.85 CHF
10/3/202537.35 CHF
10/2/202536.65 CHF
10/1/202536.95 CHF
9/30/202536.25 CHF
9/29/202536.15 CHF
9/26/202535.40 CHF
9/25/202536.05 CHF
9/24/202536.55 CHF
9/23/202536.85 CHF
9/22/202536.90 CHF
9/19/202536.40 CHF
9/18/202535.60 CHF
9/17/202535.75 CHF
9/16/202535.25 CHF
9/15/202534.90 CHF
9/12/202535.25 CHF
9/11/202535.25 CHF
9/10/202534.85 CHF
9/9/202534.55 CHF
9/8/202533.75 CHF
9/5/202534.25 CHF
9/4/202533.95 CHF
9/3/202534.25 CHF
9/2/202533.35 CHF
9/1/202532.35 CHF
8/29/202532.00 CHF
8/28/202532.40 CHF
8/27/202532.50 CHF
8/26/202532.05 CHF
8/25/202532.45 CHF
8/22/202532.95 CHF
8/21/202532.50 CHF
8/20/202532.00 CHF
8/19/202532.55 CHF
8/18/202533.00 CHF
8/15/202532.30 CHF
8/14/202531.65 CHF
8/13/202531.75 CHF
8/12/202531.25 CHF
8/11/202531.30 CHF
Access this data via the Eulerpool API
Get Free API Key

BB Biotech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
-396.22 M CHF
-403.76 M CHF
-404.81 M CHF
Jan 1, 2022
-351.23 M CHF
-356.03 M CHF
-357.81 M CHF
Jan 1, 2023
35,000.00 CHF
-29.93 M CHF
-206.61 M CHF
Jan 1, 2024
111.63 M CHF
84.40 M CHF
75.90 M CHF
Jan 1, 2025
76.81 M CHF
586.83 M CHF
578.13 M CHF
Jan 1, 2026 (e)
1.28 B CHF
-33.50 M CHF
141.47 M CHF
Jan 1, 2027 (e)
1.28 B CHF
-33.50 M CHF
110.76 M CHF
Jan 1, 2028 (e)
1.28 B CHF
-33.50 M CHF
102.53 M CHF

BB Biotech Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 9, 2026, 10:30 PM
 
REVENUEB CHF
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB CHF
EBITB CHF
EBIT MARGIN%
NET INCOMEB CHF
NET INCOME GROWTH%
DIV.CHF
DIV. GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
0.941.480.66-0.800.69-0.470.690.70-0.40-0.35–0.110.081.281.281.28
149.2057.52-55.35-220.79-187.06-167.10-247.312.04-156.65-11.36––-31.531,582.89––
100.00100.00100.00100.00100.00100.00100.00100.00100.00100.00–100.00100.00100.00100.00100.00
0.941.480.66-0.800.69-0.470.690.70-0.40-0.350.080.110.081.281.281.28
0.931.470.65-0.830.69-0.470.680.69-0.40-0.36-0.030.080.59-0.03-0.03-0.03
99.4799.5999.09104.0299.28101.0898.8399.14101.77101.42–75.68771.05-2.58-2.58-2.58
0.931.470.65-0.800.69-0.470.680.69-0.40-0.36-0.210.080.580.140.110.10
153.6857.89-55.65-223.01-185.66-168.56-243.742.07-158.47-11.63-42.30-136.41670.67-75.61-21.99-7.27
4.507.0011.602.252.753.303.053.403.603.852.852.003.834.504.714.92
400.0055.5665.71-80.6022.2220.00-7.5811.485.886.94-25.97-29.8291.5017.494.674.46
55.2955.2955.2955.2955.4355.6255.4856.0155.3154.8654.8554.8055.1555.1555.1555.15
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales BB Biotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BB Biotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BB Biotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares BB Biotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BB Biotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

BB Biotech stock margins

The BB Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BB Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BB Biotech.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
100.00 %
101.90 %
102.17 %
Jan 1, 2022
100.00 %
101.37 %
101.87 %
Jan 1, 2023
100.00 %
-85,508.57 %
-590,305.70 %
Jan 1, 2024
100.00 %
75.61 %
67.99 %
Jan 1, 2025
99.93 %
763.99 %
752.66 %
Jan 1, 2026 (e)
99.93 %
-2.62 %
11.06 %
Jan 1, 2027 (e)
99.93 %
-2.62 %
8.66 %
Jan 1, 2028 (e)
99.93 %
-2.62 %
8.02 %

BB Biotech Stock Revenue, EBIT, Earnings per Share

The BB Biotech earnings per share therefore indicates how much revenue BB Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
-7.16 CHF
-7.30 CHF
-7.32 CHF
Jan 1, 2022
-6.40 CHF
-6.49 CHF
-6.52 CHF
Jan 1, 2023
0.00 CHF
-0.55 CHF
-3.77 CHF
Jan 1, 2024
2.04 CHF
1.54 CHF
1.39 CHF
Jan 1, 2025
1.39 CHF
10.64 CHF
10.48 CHF
Jan 1, 2026 (e)
23.33 CHF
-0.61 CHF
2.58 CHF
Jan 1, 2027 (e)
23.33 CHF
-0.61 CHF
2.02 CHF
Jan 1, 2028 (e)
23.33 CHF
-0.61 CHF
1.87 CHF

BB Biotech business model & stock analysis

BB Biotech AG is a Swiss investment company specializing in biotechnology and life sciences. The company was founded in 1993 and has been listed on the SIX Swiss Exchange since 1995. BB Biotech AG primarily invests in publicly traded companies in Europe and North America that are active in the biotechnology and healthcare industry. The business model of BB Biotech AG is based on a combination of active portfolio management and long-term investment strategy. The company invests in stocks of biotechnology and healthcare companies that typically do not yet generate profits but are developing promising products or technologies. BB Biotech AG focuses on high portfolio diversification to minimize risk. BB Biotech AG is divided into three business areas: biotechnology, pharmaceuticals, and medtech. The emphasis is on biotechnology, where the company invests in stocks of well-known biotech companies such as Celgene, Gilead Sciences, Regeneron, and Biogen. In the pharmaceutical sector, BB Biotech AG invests in large pharmaceutical companies like Roche, Novartis, or Pfizer. In the medtech sector, the company invests in companies specializing in the development of medical devices and instruments, such as Intuitive Surgical or Neurocrine Biosciences. BB Biotech AG provides added value to its investors through continuous monitoring of the companies in the portfolio and risk management. The company ensures that investors are always informed about the latest developments in the biotechnology and healthcare industry and regularly publishes reports about the portfolio. The portfolio of BB Biotech AG consists of over 30 different biotech, pharmaceutical, and medtech companies. The main holdings of BB Biotech AG are Celgene, Gilead Sciences, Biogen, Incyte, Vertex Pharmaceuticals, Regeneron, and Neurocrine Biosciences. Celgene is one of the world's leading biotech companies specializing in the development of drugs against cancer and other serious diseases. Gilead Sciences is a biotech company specializing in the research of new therapies for the treatment of infectious diseases such as HIV and hepatitis. Biogen is a biotech company specializing in the treatment of neurological disorders such as multiple sclerosis. Incyte is a biotech company specializing in the development of drugs against cancer and inflammatory diseases. Vertex Pharmaceuticals is a biotech company specializing in the treatment of cystic fibrosis. Regeneron is a biotech company specializing in the development of drugs against eye diseases such as macular degeneration and other serious diseases. Neurocrine Biosciences is a medtech company specializing in the development of drugs against sleep disorders and other neurological diseases. BB Biotech AG is an important player in the market for biotechnology and healthcare investments. Through smart selection of investment targets and systematic risk monitoring, the company has enabled investors to achieve high returns with comparatively low risk. Due to these factors, it is now one of the most important holdings in the biotechnology and healthcare sector.

BB Biotech SWOT Analysis

Strengths

  • Strong market position with a diversified portfolio of healthcare and biotechnology companies.
  • Experienced and knowledgeable management team with a successful track record in the industry.
  • Access to a wide range of investment opportunities in the healthcare sector.

Weaknesses

  • Vulnerability to changes in regulations and policies affecting the healthcare and biotech industries.
  • Dependency on the performance and success of its portfolio companies.
  • Limited ability to influence the strategic decisions of its portfolio companies.

Opportunities

  • Growing demand for innovative healthcare solutions and advancements in biotechnology.
  • Potential for significant returns on investments in high-growth companies in the healthcare sector.
  • Possibility of strategic partnerships and collaborations in the industry.

Threats

  • Intense competition within the healthcare and biotechnology sectors.
  • Economic downturns and market volatility affecting investor sentiment.
  • Risks associated with clinical trial failures and regulatory challenges.

BB Biotech Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

BB Biotech historical P/E ratio, EBIT multiple, and P/S ratio

BB Biotech annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

BB Biotech shares outstanding

The number of shares of BB Biotech was 55.15 M in 2025. This indicates how many shares BB Biotech is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
55.31 M Stocks
Jan 1, 2022
54.86 M Stocks
Jan 1, 2023
54.85 M Stocks
Jan 1, 2024
54.80 M Stocks
Jan 1, 2025
55.15 M Stocks
Jan 1, 2026 (e)
55.15 M Stocks
Jan 1, 2027 (e)
55.15 M Stocks
Jan 1, 2028 (e)
55.15 M Stocks

BB Biotech stock splits

In BB Biotech's history, there have been no stock splits.

BB Biotech Dividend History

17 years of dividend payments

YearAnnual DividendYoY ChangePayments
20264.50CHFYTD—2×
Mar 20, 20262.25CHF↑ 10.8%1/2
Mar 23, 20262.25CHF 0.0%2/2
20253.83CHF↑ 91.5%2×
Mar 21, 20251.80CHF↓ 10.0%1/2
Mar 24, 20252.03CHF↑ 12.8%2/2
20242.00CHF↓ 29.8%1×
20232.85CHF↓ 26.0%1×
20223.85CHF↑ 6.9%1×
20213.60CHF↑ 5.9%1×
20203.40CHF↑ 11.5%1×
20193.05CHF↓ 7.6%1×
20183.30CHF↑ 20.0%1×
20172.75CHF↑ 22.2%1×

BB Biotech dividend history and estimates

In 2025, BB Biotech paid a dividend amounting to 3.83 CHF. Dividend means that BB Biotech distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
3.60 CHF
0.00 CHF
Jan 1, 2022
3.85 CHF
0.00 CHF
Jan 1, 2023
2.85 CHF
0.00 CHF
Jan 1, 2024
2.00 CHF
0.00 CHF
Jan 1, 2025
3.83 CHF
0.00 CHF
Jan 1, 2026
4.50 CHF
0.00 CHF
Jan 1, 2027 (e)
0.00 CHF
4.71 CHF
Jan 1, 2028 (e)
0.00 CHF
4.92 CHF

BB Biotech dividend payout ratio

In 2025, BB Biotech had a payout ratio of 17.17%. The payout ratio indicates the percentage of the company's profits that BB Biotech distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
-49.19 %
Jan 1, 2022
-59.03 %
Jan 1, 2023
-75.66 %
Jan 1, 2024
144.40 %
Jan 1, 2025
17.17 %
Jan 1, 2026 (e)
174.42 %
Jan 1, 2027 (e)
232.94 %
Jan 1, 2028 (e)
263.11 %

Current BB Biotech forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
90.00 % (9)
Hold
10.00 % (1)
Sell
0.00 % (0)
12M Price Target
58.87
Last Price
52.10
Currency
CHF
12M Return Potential
13.00 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the BB Biotech stock

58/100
71
Environment
33
Social
71
Governance
E

Environment

20
Scope 1 - Direct Emissions10
Scope 2 - Indirect emissions from purchased energy23
Scope 3 - Indirect emissions within the value chain575
Total CO₂ emissions33
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

BB Biotech shareholder structure

% Name
1.94502%
Zürcher Kantonalbank (Asset Management)
Zürcher Kantonalbank (Asset Management)
0.91852%
Saba Capital Management, L.P.
Saba Capital Management, L.P.
0.54713%
Mirabaud Asset Management AG
Mirabaud Asset Management AG
0.28889%
BlackRock Advisors (UK) Limited
BlackRock Advisors (UK) Limited
0.26082%
Banque Cantonale Vaudoise
Banque Cantonale Vaudoise
0.17674%
Union Bancaire Privée, UBP SA
Union Bancaire Privée, UBP SA

BB Biotech Beneficial Ownership Filings (SEC 13D/G)

Free Float
99.5%
Float Shares
-
Shares Outstanding
-

BB Biotech Executives and Management Board

15 members · avg. age 63 · 40 % women

Management

AA

Dr. Anna Aguado

Member Investment Management Team

–
MB

Dr. Maurizio Bernasconi

Deputy Head of the Investment Management Team

–
CB

Dr. Can Buldun-Gora

Member of the Investment Management Team - Data Scientist

–
SC

Dr. Samuel Croset

Member of the Investment Management Team - Data Scientist

–
LG

Dr. Leonidas Georgiou

Member of the Investment Management Team

–
CK

Dr. Christian Koch

Head of the Investment Management Team

–

Board of Directors

TP

Dr. Thomas Von Planta (64)

Independent Chairman of the Board

376,021.00 CHF
CM

Dr. Clive Meanwell (68)

Independent Vice Chairman of the Board · since 2004

280,000.00 CHF
LH

Ms. Laura Hamill (61)

Independent Director

260,000.00 CHF
PH

Dr. Pearl Huang (68)

Independent Director

260,000.00 CHF
PT

Prof. Dr. Mads Thomsen (65)

Independent Director

240,000.00 CHF
CS

Ms. Camilla Soenderby (53)

Independent Director

193,808.00 CHF

BB Biotech Supply Chain

BB Biotech Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#NameTrend
1
Bellevue Group
Supplier·Capital Markets·CH
0.36
0.70
0.80
0.58
0.61
0.54

Frequently asked questions about BB Biotech

BB Biotech AG is a biotechnology investment company headquartered in Switzerland. The company primarily focuses on investing in a portfolio of innovative and promising biotechnology companies, with a particular emphasis on companies developing and commercializing breakthrough therapies. BB Biotech AG aims to support and generate long-term value by investing in cutting-edge biotech companies that address unmet medical needs and have strong growth potential. By leveraging their extensive expertise and network within the biotech industry, BB Biotech AG aims to provide investors with an attractive investment opportunity in the rapidly evolving field of biotechnology.

BB Biotech AG is primarily active in the biotechnology industry.

Some of the main competitors of BB Biotech AG in the market include Roche Holding AG, Novartis AG, and Johnson & Johnson.

BB Biotech AG is a renowned Swiss investment company specializing in the healthcare sector. Established in 1993, BB Biotech has a rich history of success in generating long-term value for its shareholders. The company primarily focuses on investing in innovative biotech companies that exhibit strong growth potential. BB Biotech benefits from an experienced team of professionals dedicated to thoroughly assessing and selecting promising investment opportunities within the biotech industry. With its extensive expertise and broad network, BB Biotech seeks to capitalize on cutting-edge advancements in the healthcare sector. Throughout its history, BB Biotech has consistently delivered impressive returns for investors, solidifying its position as a leading player in the biotech investment space.

BB Biotech AG has achieved significant milestones in its history. Some notable achievements include the successful launch of its investment strategy focused on globally listed biotech companies. The company has also been able to deliver consistent returns to its shareholders, with a strong track record of portfolio performance. BB Biotech AG has established itself as a leader in the biotech sector, with a well-diversified portfolio of investments in innovative companies. The company has also been actively involved in supporting the development of breakthrough therapies and advancements in the biotech industry. Overall, BB Biotech AG's achievements reflect its commitment to supporting the growth and success of the biotech sector.

BB Biotech AG is primarily present in Switzerland and Germany.

BB Biotech AG represents strong values and a solid corporate philosophy. As a leading biotech investment company, BB Biotech AG focuses on long-term capital appreciation through investments in the biotechnology industry. They strive to support innovative companies that develop cutting-edge therapies and healthcare solutions. This strategy aligns with their commitment to drive advancements and improvements in the healthcare sector. By investing in emerging biotech companies with significant growth potential, BB Biotech AG aims to generate sustainable returns for its shareholders.

Analysts currently set an average price target of 58.28 CHF for the BB Biotech stock (median: 58.87 CHF), implying +11.9 % versus the latest price. The consensus is based on 10 analyst ratings.

BB Biotech Analyst Price Targets 2026

10 analysts currently rate the BB Biotech stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect BB Biotech to generate revenue of 1.28 B CHF and earnings per share of 2.57 CHF.

BB Biotech Analyst Price Targets 2026

Converted at the current exchange rate, the BB Biotech share trades at 55.12 EUR (51.50 CHF).

The BB Biotech share (BION.SW) is listed on 6 stock exchanges, including: XETRA (BBZA.DE), München (BBZA.MU), Düsseldorf (BBZA.DU), Hamburg (BBZA.HM), London (0JYO.L), SIX (Zürich) (BION.SW).

BB Biotech AG is a Swiss investment company specializing in biotechnology. The company actively invests worldwide in biotechnology companies working on innovative therapies to combat various diseases. Their approach focuses on companies developing medications and therapies based on genomic and protein research. The business model of BB Biotech AG is based on their position as strong and experienced investors in the biotechnology field. They invest in a variety of companies within their portfolio that focus on the development of innovative therapeutic options. The company strives for long-term success by investing in companies that utilize innovative technologies for drug manufacturing. BB Biotech AG is a key player in the global biotech market and a significant investor in this sector. In addition to their investment strategy, BB Biotech AG also offers comprehensive consulting services and expertise in the biotechnology and life sciences field. The company supports biotechnology companies in various stages of development, from research and development to drug approval and marketing. Their portfolio includes companies from various areas of biotechnology and life sciences, including biopharmaceuticals, diagnostics, medical technology, and genomics. Some of the key companies in their portfolio are Biotechnology Innovation Organization, Regeneron Pharmaceuticals, Gilead Sciences, Vertex Pharmaceuticals, and Blueprint Medicines. The company aims to actively manage and optimize their portfolio to provide investors with the highest benefit. Through careful research, analysis, and monitoring of biotechnology markets worldwide, BB Biotech AG is able to identify opportunities and act in a timely manner. Overall, BB Biotech AG offers an innovative business model based on a deep understanding of the biotechnology industry and a comprehensive portfolio of companies utilizing innovative technologies for drug manufacturing. The company provides comprehensive investment and consulting services and is a major player in the global biotech market.

The expected revenue of BB Biotech is 1.28 B CHF. This figure is based on current financial data and reflects the company's business performance.

The expected profit of BB Biotech is 141.47 M CHF. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of BB Biotech is currently 20.08. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BB Biotech stock.

The price-to-sales ratio (P/S) of BB Biotech is currently 2.22. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BB Biotech stock.

The Eulerpool Quality Score for BB Biotech is 4/10.

The ISIN of BB Biotech is CH0038389992. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of BB Biotech is A0NFN3. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of BB Biotech is BION.SW. The ticker symbol is used to trade BB Biotech shares on the stock exchange.

Over the past 12 months, BB Biotech paid a dividend of 3.83 CHF . This corresponds to a dividend yield of about 7.44 %. For the coming 12 months, BB Biotech is expected to pay a dividend of 4.71 CHF.

The current dividend yield of BB Biotech is 7.44 %.

BB Biotech pays a dividend, distributed in the months of , , , .

BB Biotech paid dividends every year for the past 13 years.

For the upcoming 12 months, dividends amounting to 4.71 CHF are expected. This corresponds to a dividend yield of 9.14 %.

BB Biotech is assigned to the '—' sector.

To receive the latest dividend of BB Biotech from amounting to 2.25 CHF, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, BB Biotech distributed 2 CHF as dividends.

The dividends of BB Biotech are distributed in CHF.

All fundamentals and in-depth analysis of BB Biotech

Our stock analysis for BB Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BB Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

BB Biotech Stock
BB Biotech Revenue→
BB Biotech Stock
BB Biotech Net Income→
BB Biotech Stock
BB Biotech P/E→
BB Biotech Stock
BB Biotech P/S→
BB Biotech Stock
BB Biotech EBIT→
BB Biotech Stock
BB Biotech Dividend→
BB Biotech Stock
BB Biotech Directors Dealings→
BB Biotech Stock
BB Biotech Stocks→
BB Biotech Stock
BB Biotech Market capitalization→
BB Biotech Stock
BB Biotech Debt→
BB Biotech Stock
BB Biotech Liabilities→
BB Biotech Stock
BB Biotech Equity→
BB Biotech Stock
BB Biotech AAQS→
BB Biotech Stock
BB Biotech Employees→
BB Biotech Stock
BB Biotech ROE→
BB Biotech Stock
BB Biotech ROA→
BB Biotech Stock
BB Biotech ROCE→
BB Biotech Stock
BB Biotech News→
BB Biotech Stock
BB Biotech Analyst Price Targets→

— Stocks

BB LiquidatingBazel InternationalBbb FoodsBayview AcquisitionBbia CoBaysideBBK Test Systems CoBayridge ResourcesBCL EnterprisesBaweja StudiosBE ResourcesBausenAll Stocks A–Z →